Dendreon files for Chapter 11 bankruptcy - Puget Sound Business Jour...

11/10/14

Dendreon files for Chapter 11 bankruptcy
Puget Sound Business Journal (Seattle) (blog)
Dendreon Corp., the Seattle biotech that developed the prostate cancer drug Provenge, has filed for Chapter 11 bankruptcy protection. Dendreon was looking at $620 million in debt that was coming due in January 2016. The company said it reached a deal ...